Loading
Dutch researchers showed that the RNA inside blood platelets changes when cancer is present, enough to detect 18 cancer types in a laboratory comparison, though people with other illnesses often tested falsely positive.
In 't Veld and colleagues used tumour-educated platelet RNA sequencing (thromboSeq) to detect 18 cancer types. At 99% specificity in asymptomatic controls it detected cancer in two-thirds of 1,096 samples from patients with stage I to IV cancer and in half of 352 stage I to III tumours. Symptomatic controls, including inflammatory and cardiovascular disease and benign tumours, had more false positives, with an average specificity of 78%. The tumour site of origin was correct in over 80% for five tumour types.
A different source of signal, the platelets, with the warning every multi-cancer test faces: people who are ill with something else are more often flagged wrongly.
Shares RNA sequencing & expression profiling, Multi-cancer early detection (MCED).
Shares RNA sequencing & expression profiling, Multi-cancer early detection (MCED).
Shares RNA sequencing & expression profiling, Multi-cancer early detection (MCED).
Shares RNA sequencing & expression profiling, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/